Magenta Therapeutics Completes $48.5M Series A Financing

magentaMagenta Therapeutics, a Cambridge, Mass.-based biotechnology company that develops therapeutics leveraging stem cell biology and bone marrow transplant, completed a $48.5M Series A financing.

The round was led by Third Rock Ventures and Atlas Venture with participation from GV (formerly Google Ventures), Access Industries (Blavatnik Group) and Partners Innovation Fund.

Led by Jason Gardner, D. Phil., chief executive officer, president and cofounder, Michael Cooke Ph.D., chief scientific officer; Bastiano Sanna Ph.D., chief operating officer; and Christina Isacson Ph.D., vice president, head of business development, Magenta Therapeutics is a biotechnology company applying new stem cell science to reboot the immune and blood systems to treat patients with autoimmune diseases, genetic blood disorders and cancer.
Through a license agreement with Harvard University, the company has access to a portfolio of stem cell technologies developed at Harvard, Massachusetts General Hospital and Boston Children’s Hospital.

Magenta was founded by internationally recognized experts in stem cell medicine including:
– David Scadden, M.D., Gerald and Darlene Jordan Professor of Medicine, Professor of Stem Cell and Regenerative Biology, and chair of the Department of Stem Cell and Regenerative Biology, Harvard University; director of the Center for Regenerative Medicine, Massachusetts General Hospital; co-founder and co-director, Harvard Stem Cell Institute
– Derrick Rossi, Ph.D., associate professor of Stem Cell and Regenerative Biology, Harvard University; investigator, Program in Cellular and Molecular Medicine, Boston Children’s Hospital; principal faculty member, Harvard Stem Cell Institute
– John Dipersio, M.D., Ph.D., professor of Medicine, Pediatrics and Pathology/Immunology, chief, Division of Oncology, Siteman Cancer Center, Barnes Jewish Hospital, Washington University St. Louis School of Medicine
– Robert Negrin, M.D., professor of Medicine, Division chief of the Blood and Marrow Transplant Program; medical director of the Clinical Bone Marrow Transplantation Laboratory, Stanford University
– Luigi Naldini, M.D., Ph.D., director, San Raffaele-Telethon Institute for Gene Therapy, Milan (TIGET)
– Alan Tyndall, M.D., emeritus professor and head of Rheumatology, Co-founder, Basel Stem Cell Network, University of Basel



Join the discussion